- Home
- SENEB vs CMMB Comparison
SENEB vs CMMB Comparison
Compare SENEB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- CMMB
- Stock Information
- Founded
- SENEB 1949
- CMMB 2004
- Country
- SENEB United States
- CMMB Israel
- Employees
- SENEB N/A
- CMMB N/A
- Industry
- SENEB Packaged Foods
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- CMMB Health Care
- Exchange
- SENEB Nasdaq
- CMMB Nasdaq
- Market Cap
- SENEB N/A
- CMMB 23.0M
- IPO Year
- SENEB N/A
- CMMB N/A
- Fundamental
- Price
- SENEB $107.99
- CMMB $1.21
- Analyst Decision
- SENEB
- CMMB Strong Buy
- Analyst Count
- SENEB 0
- CMMB 2
- Target Price
- SENEB N/A
- CMMB $8.50
- AVG Volume (30 Days)
- SENEB 518.0
- CMMB 186.3K
- Earning Date
- SENEB 08-07-2025
- CMMB 08-20-2025
- Dividend Yield
- SENEB N/A
- CMMB N/A
- EPS Growth
- SENEB N/A
- CMMB N/A
- EPS
- SENEB 5.90
- CMMB N/A
- Revenue
- SENEB $1,578,887,000.00
- CMMB N/A
- Revenue This Year
- SENEB N/A
- CMMB N/A
- Revenue Next Year
- SENEB N/A
- CMMB N/A
- P/E Ratio
- SENEB $17.91
- CMMB N/A
- Revenue Growth
- SENEB 8.25
- CMMB N/A
- 52 Week Low
- SENEB $57.51
- CMMB $0.87
- 52 Week High
- SENEB $107.99
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SENEB 94.49
- CMMB 37.38
- Support Level
- SENEB $85.79
- CMMB $1.17
- Resistance Level
- SENEB $94.02
- CMMB $1.22
- Average True Range (ATR)
- SENEB 0.34
- CMMB 0.06
- MACD
- SENEB 1.52
- CMMB -0.01
- Stochastic Oscillator
- SENEB 100.00
- CMMB 37.50
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.